592 related articles for article (PubMed ID: 29749540)
1. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
2. Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review.
Bryukhovetskiy I; Pak O; Khotimchenko Y; Bryukhovetskiy A; Sharma A; Sharma HS
Int Rev Neurobiol; 2020; 151():67-98. PubMed ID: 32448615
[TBL] [Abstract][Full Text] [Related]
3. TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.
Ghosh D; Ulasov IV; Chen L; Harkins LE; Wallenborg K; Hothi P; Rostad S; Hood L; Cobbs CS
Stem Cells; 2016 Sep; 34(9):2276-89. PubMed ID: 27354342
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Liu YC; Lee IC; Chen PY
J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells in glioblastoma.
Lathia JD; Mack SC; Mulkearns-Hubert EE; Valentim CL; Rich JN
Genes Dev; 2015 Jun; 29(12):1203-17. PubMed ID: 26109046
[TBL] [Abstract][Full Text] [Related]
6. Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells.
Volovetz J; Berezovsky AD; Alban T; Chen Y; Lauko A; Aranjuez GF; Burtscher A; Shibuya K; Silver DJ; Peterson J; Manor D; McDonald JA; Lathia JD
Cell Death Dis; 2020 Feb; 11(2):152. PubMed ID: 32102991
[TBL] [Abstract][Full Text] [Related]
7. Targeting glioblastoma cancer stem cells: the next great hope?
Khan IS; Ehtesham M
Neurosurg Focus; 2014 Dec; 37(6):E7. PubMed ID: 25581936
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.
Biserova K; Jakovlevs A; Uljanovs R; Strumfa I
Cells; 2021 Mar; 10(3):. PubMed ID: 33799798
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
11. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
13. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches.
Shakya S; Gromovsky AD; Hale JS; Knudsen AM; Prager B; Wallace LC; Penalva LOF; Brown HA; Kristensen BW; Rich JN; Lathia JD; Brown JM; Hubert CG
Acta Neuropathol Commun; 2021 May; 9(1):101. PubMed ID: 34059134
[TBL] [Abstract][Full Text] [Related]
14. Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Farace C; Oliver JA; Melguizo C; Alvarez P; Bandiera P; Rama AR; Malaguarnera G; Ortiz R; Madeddu R; Prados J
PLoS One; 2015; 10(7):e0134111. PubMed ID: 26230845
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
16. Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review).
Bryukhovetskiy I; Bryukhovetskiy A; Khotimchenko Y; Mischenko P
Oncol Rep; 2016 Feb; 35(2):639-48. PubMed ID: 26548844
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of the interaction between glioblastoma CD133
Shevchenko V; Arnotskaya N; Pak O; Sharma A; Sharma HS; Khotimchenko Y; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():155-169. PubMed ID: 32448605
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth.
Setti M; Osti D; Richichi C; Ortensi B; Del Bene M; Fornasari L; Beznoussenko G; Mironov A; Rappa G; Cuomo A; Faretta M; Bonaldi T; Lorico A; Pelicci G
Oncotarget; 2015 Oct; 6(31):31413-27. PubMed ID: 26429879
[TBL] [Abstract][Full Text] [Related]
20. Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas.
Muñoz DM; Guha A
Oncotarget; 2011 Aug; 2(8):590-8. PubMed ID: 21896959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
